Metastatic Breast Cancer
Conditions
Keywords
breast cancer, Indibulin, unresectable, locally advanced breast cancer
Brief summary
This study is a Phase I/II trial of a novel Indibulin dosing schedule for the treatment of metastatic breast cancer. Eligible patients will have measurable or non-measurable, metastatic or unresectable, locally advanced breast cancer and may have received any number of prior therapies for their disease. It is expected that the Phase I portion will enroll up to 20 patients and the Phase II portion will enroll up to 45 patients.
Interventions
DRUGIndibulin
Indibulin given orally once a day for 5 days followed by a 9 day rest
Sponsors
Memorial Sloan Kettering Cancer Center
Alaunos Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic or cytologic confirmation of invasive carcinoma of the breast. * Clinical evidence of metastatic disease or locally advanced disease not amenable to curative therapy. * Measurable or non-measurable lesions according to the RECIST Version 1.1 2009. * Any number of prior endocrine, biologic or chemotherapy regimens is permitted. All previous chemotherapy and biologic therapy must have been discontinued at least 3 weeks prior to beginning study drug. Endocrine therapy may not be used concurrently with protocol treatment. All acute toxic effects (excluding alopecia or neuropathy) of any prior therapy must have resolved to NCI CTC (version 4.0) Grade ≤ 1 or to baseline * Prior radiation therapy is permitted. * ECOG performance status of 0, 1 or 2. * Age ≥ 18 years * Life expectancy ≥ 12 weeks * Patients with HER2-positive (IHC 3+ or FISH-amplified) breast cancer must have received trastuzumab or have a contradiction to receiving HER2- targeted therapy (such as abnormal left ventricular ejection fraction)as determined by the treating physician. * Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: * Creatinine ≤ 1.5x upper limit of normal (ULN) * Total bilirubin ≤ 1.5x ULN * ALT or AST ≤ 2.5x ULN * ANC ≥ 1.5 x10(9)/L * Platelets ≥ 100 x10(9)/L * Hemoglobin ≥ 9g/dL * Subjects of childbearing potential must agree to use a barrier method of contraception throughout the study and for 3 months after study drug administration.
Exclusion criteria
* Pregnant or nursing women may not participate. * Serious, uncontrolled, concurrent infection. * Patients with symptomatic CNS metastases that remain untreated by radiation therapy are excluded from this trial. The presence of asymptomatic, previously irradiated, stable brain metastases for at least 3 months are not grounds for trial exclusion. * Presence of uncontrolled gastrointestinal malabsorption syndrome. * Any chemotherapy, radiotherapy or breast cancer directed biologic therapy during the study or within 3 weeks of study start. Mitomycin C or nitrosureas should not be given within 6 weeks of study entry. No washout period is required for hormonal therapies. * Concurrent radiation therapy is not permitted during treatment on protocol. * History of an invasive second primary malignancy diagnosed within the previous 3 years, except for Stage I endometrial or cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer. * Any medical, psychological or social condition that may interfere with the subject's ability to safely participate in the study. * Unwillingness to give written informed consent or unwillingness to participate or inability to comply with the protocol for the duration of the study. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures are necessary for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase I- Maximum Tolerated Dose | Throughout Cycle 1 (28 days) | The primary objective of the Phase I portion of the trial is to determine the maximum tolerated dose (MTD) of Indibulin when given for 5 days followed by a 9 day rest (5-9) using a standard 3+3 dose escalation scheme for the treatment of metastatic breast cancer |
| Phase II- Progression Free Survival | 4 months | The primary objective of the Phase II portion of this trial is to examine the efficacy of indibulin for the treatment of metastatic breast cancer at the MTD established in Phase I. The primary endpoint is the proportion of patients who are progression free at 4 months when treated with Indibulin (5-9)at the MTD determined by the phase I portion of the trial. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase I- Pharmacokinetics of indibulin in study subject plasma assessed in Cycle 1 Day 1 and Cycle 1 Day 5 per schedule below in Description section. | During Cycle 1 (28 days) | To evaluate pharmacokinetics (PK) of Indibulin (5-9) as it is assessed in Cycle 1 Day 1, Day 2, Day 5 and Day 8. Cycle 1 PK schedule as follows: Day 1 immediately pre dose, 1 hour, 2 hours, 4 hours, 6 hours and approximately 24 hours after start of infusion (Cycle 2 Day 1), Day 5 pre-dose and at anytime during Day 8. |
| Phase II- Overall Response Rate | At the end of Cycles 4 and 6 (approximately 4 months and 6 months respectively) | To estimate the overall response rate (complete response and partial response)associated with Indibulin (5-9) schedule at eth MTD determined by the Phase I portion of this trial in patients with metastatic breast cancer. |
| Phase I- Number of participants with Adverse Events as a measure of safety and tolerability | Duration of study, approximately one year | To evaluate the safety of Indibulin when administered for 5 days followed by a 9 day rest (5-9) in patients with metastatic breast cancer |
| Phase II- Number of patients with Adverse Events as a measure of safety and tolerability | Throughout study, approximately one year | To evaluate the safety of Indibulin when administered for 5 days followed by a 9 day rest (5-9) at the MTD determined by the Phase I portion of this trial in patients with metastatic breast cancer. |
| Phase II- Rate of Stable Disease | Phase II- greater than 6 months | To estimate the rate of stable disease greater than 6 months associated with the Indibulin (5-9) schedule at the MTD determined by the the Phase I portion of this trial in patients with metastatic breast cancer. |
| Phase I- Toxicity | Cycle 1 (28 days), and duration of study (approximately one year) | To describe the Cycle I and overall toxicity rates of indibulin (5-9) using the NCI CTC version 3. |
Countries
United States
Outcome results
None listed